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Introduction
Radiographs are widely accepted as the ‘gold standard’ in
assessing structural joint damage associated with rheuma-
toid arthritis (RA) and are therefore essential in evaluating
the efficacy of experimental therapeutics. Both traditional
drugs, such as sulfasalazine and methotrexate (MTX), and
new drugs, such as leflunomide and biologic agents, can
reduce the progression of radiologic damage [1–6]. With
the development of agents that have a beneficial impact
on structural joint damage, it has become tempting to
retrospectively compare the efficacy results from various
RA trials. However, it is difficult, if not impossible, to
compare across clinical trials, and clinicians need to be
aware of the limitations in comparing radiographic data.
This paper discusses these limitations and offers guid-
ance on how to interpret the results of clinical trials.
Limitations in comparing data across clinical
trials
Knowledge of the limitations in comparing radiographic
data across clinical trials is necessary for accurate inter-
pretation of data in the absence of direct, head-to-head
trials. These limitations include differences in study design,
patient characteristics, severity of disease, duration of
follow-up, scoring method used, reader reliability, order in
which radiographs are read, handling of missing data, and,
finally, data presentation. Each of these limitations is dis-
cussed below.
Study design
Some trials use a parallel design with patients who have
not previously received treatment for RA. An example of
this is the MTX arm in the etanercept trial, in which
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patients with early RA who were naive to MTX treatment
were randomized to an MTX treatment arm or an etaner-
cept treatment arm [5]. Other trials included patients who
were previously treated and who experienced a partial
response to a disease-modifying antirheumatic drug. An
example of this study design is the Anti-TNF [tumor necro-
sis factor] Trial in Rheumatoid Arthritis with Concomitant
Therapy (ATTRACT), in which patients who had previously
been treated with MTX were randomized to groups
treated with infliximab plus MTX or with MTX alone [4].
Although both studies included treatment arms in which
patients received MTX alone, the MTX arm in the etaner-
cept trial is not comparable with the MTX arm in the
ATTRACT trial, because of the different baseline charac-
teristics and treatment histories of the patient populations.
It can be expected that the radiographic response to MTX
in patients naive to this drug will be more pronounced (on
a population level) compared with patients who have
previously shown a partial response to MTX and then con-
tinued treatment with this drug. Therefore, it is important
to be aware of the study designs before comparing data
between trials.
Patient characteristics
Several prognostic factors are known to predict an unfa-
vorable outcome with respect to structural joint damage.
The most important of these are the presence of rheuma-
toid factor, evidence of joint erosion early in the course of
the disease, and rapid disease progression [7]. However,
these predictors account for only a limited percentage of
the variation between patients. Further, although these
predictors are valid for groups of patients, they have little
value when applied to individual patients. In addition, it is
likely that other, currently unknown, factors will be associ-
ated with structural joint damage. By sampling from one
patient population and randomizing the enrolled patients
over two (or more) comparative trial arms, investigators
can reasonably assume that both known and unknown
factors are well balanced between the treatment arms.
However, if trial arms from various studies are compared,
this randomization has not taken place and many hidden
differences between the patient populations may exist.
Although prognostic factors listed previously relate to the
progression of structural joint damage, they are not neces-
sarily transferable to predicting response to therapy.
Anderson et al. [8] investigated the prognostic factors for
response to treatment in 14 randomized clinical trials. The
investigators concluded that patients whose RA is of
longer duration do not respond as well to treatment as do
patients with early disease. Moreover, female gender, pre-
vious treatment with a disease-modifying antirheumatic
drug, poorer functional class, and higher disease activity
affect the likelihood of patient response to treatment.
According to Anderson et al. [8], these factors should also
be considered when interpreting data from clinical trials.
Baseline radiographic damage
Patients enrolled in clinical trials have different levels of
structural joint damage. Depending on the eligibility crite-
ria for a study, patients in one study may have substantially
more baseline radiographic damage than patients in
another study. Therefore, baseline radiographic damage
represents another important obstacle to comparisons
across clinical trials. Expressing this baseline damage in
terms of disease duration results in a radiographic pro-
gression rate. Recently, in two different studies, the radi-
ographic progression rate before entering the study was
shown to be an important predictor of treatment outcome
[9,10]. The ATTRACT trial was conducted in patients with
established disease who had achieved a partial response
to MTX. Patients were randomized to four active treatment
arms with infliximab and a control arm with placebo, with
all patients continuing on MTX [4]. The Combinatiethera-
pie Bij Reumatoide Artritis [Combination Therapy in
Rheumatoid Arthritis] (COBRA) trial was performed in
patients with early disease who were randomized to either
a combination of high-dose prednisone (quickly tapered)
combined with MTX and sulfasalazine, or to sulfasalazine
alone [3]. Although these trials were based on patients
from different populations (patients with established
disease versus those with early disease), both trials
showed retardation of radiographic progression (infliximab
compared with placebo on an MTX background and com-
bination therapy compared with sulfasalazine alone,
respectively). Further, it was evident that within each trial,
patients with the highest radiographic progression rate at
the onset of the trial benefited most from treatment [9,10].
Duration of follow-up
At the group level, radiographic progression in RA is a
linear process [11,12]. However, progression rates and
patterns differ markedly from patient to patient [13,14].
Because radiographs show cumulative damage, differ-
ences in duration of follow-up are expected to have a large
impact on the results. Moreover, because of differences in
the patterns of progression, patient-to-patient variability
cannot be easily corrected for by dividing progression
scores by follow-up duration – for example, to calculate a
monthly rate of progression. Therefore, it is important that
the duration of follow-up be similar when radiographic pro-
gression is compared across trials.
Scoring methodology
Another important consideration when comparing radi-
ographic scores across clinical studies is the scoring
system used to assess structural joint damage. Several
scoring methods exist to assess joint radiographs. These
scoring methods evaluate different bony features, assess
different joints, and have different scoring ranges. The
most widely used methods are the Larsen and Sharp
methods, along with their modifications [15–18]. The
Larsen method uses a global grading system that mainlyS31
assesses erosive damage. The scoring range is from 0 to
200. The Sharp method assigns separate scores for ero-
sions and joint space narrowing, which are combined to
obtain a total score. The scoring range for the Sharp
method is from 0 to 314 or 448, depending on which
modified version of the method is used. Because of the
differences in scoring ranges and in the abnormalities
included in the assessment, a score of, for example, 5 in
the Larsen method cannot be directly compared with a
score obtained using the Sharp method. In some trials,
scores obtained from hand radiographs are included,
whereas in other studies, radiographs of both the hands
and feet are used. Therefore, it is important to compare
scores obtained on the same films: joints of either the
hands or the feet, or a combination of both.
Reader reliability
Clinical trials are typically designed to have one or two
observers read and score each radiograph. The use of two
observers reduces the variability in scoring and decreases
the error of measurement. Interobserver reliability is high
for the progression of scores. However, the absolute
scores from reader to reader may be significantly different.
In other words, each observer has his or her own reading
level (and is consistent with his or her own readings), and
this reading level may be clearly different from that of
another observer, but the progression seen is fairly consis-
tent between the observers. Trials are analyzed making
use of these progression scores, scored by one (pair of)
observer(s). However, when absolute scores are com-
pared across trials, another variable besides treatment,
design, and patient characteristics is introduced: a differ-
ent observer. This further complicates the comparison of
scores across trials that used different readers.
Radiograph scoring sequence
Radiographs are read either in a known sequence or in
random order. The order in which radiographs are scored
has a significant effect on the measurement error of
scores and on the ability of scores to capture disease pro-
gression accurately [19,20]. Consequently, the order in
which radiographs are read is an important factor when
comparing results across trials. However, earlier published
trials often did not present this information [19]. Therefore,
comparing results from new trials with those already pub-
lished is often problematic.
Handling of missing data
Because radiographs show cumulative structural joint
damage, missing radiographs become an important issue
in the analysis of a progressive disease such as RA.
Missing data cannot be replaced by a simple ‘last-obser-
vation-carried-forward’ procedure, as is often applied to
other data, especially in the case of long term trials.
Sensitivity analyses to investigate the effect of the missing
radiographs are warranted [6]. The aim of each trial should
be to have films of randomized patients at baseline and at
follow-up, regardless of patient status. However, this often
is not feasible, because patients, especially those who
have withdrawn, may refuse to submit to follow-up films.
Therefore, missing radiographs will continue to pose an
obstacle and data need to be analyzed in various ways to
rule out an effect of selectively missing films.
Data presentation
Clinical trials present radiographic data in a variety of
ways, which makes the comparison of data across trials
difficult. To minimize this obstacle, a roundtable confer-
ence was held to establish a minimum set of radiographic
results that should be presented in each trial [21]. Most
data are presented on a group level, either by
mean ± standard deviation (SD) or by median and
interquartile range (IQR). Because of the skewed nature of
radiographic data, the two ways of presenting the data
provide important, but completely different, information. If
a large proportion of patients in a group shows no or
minimal progression and a few patients show a signifi-
cantly higher rate of disease progression, the latter set of
patients gives much weight to the mean ± SD of the
overall group. The presentation of these data as a median
with IQR provides information on the proportion of
patients showing a specific progression. Both the
mean ± SD and the median with IQR give important and
additive information on a group level.
Other important information is the analysis at the level of
individual patients. By dichotomizing the data, statistical
power is lost. Therefore, such analysis is advised as a sec-
ondary analysis [21]. It is useful to know the percentage of
patients who show progression above a certain clinically
important level. However, the decision about what level to
use as a cutoff is often arbitrary and can result in incompa-
rability between trials. Although some trials simply define
no progression as a score of zero, this finding does not
take into account measurement error, which is always
present. Others use arbitrary cutoff values or base the
cutoff level on the SDD (smallest detectable difference
apart from measurement error), which is a trial-specific
number [22,23]. In the leflunomide trials published by
Sharp et al. [6], the cutoff value regarded as indicating
progression in erosion was a score of 3, which resulted in
progression of erosions being reported in 3% to 11% of
treated patients (receiving leflunomide, sulfasalazine, or
MTX), versus 12% to 17% of patients receiving placebo.
In the ATTRACT trial, an SDD of the total score (in this
case, 8.6) was selected as the cutoff value in reporting
progression. In this trial, 6% of treated patients were
reported to have shown progression of erosion, versus
31% of patients receiving placebo [4]. In the etanercept
trial, 0 was selected as the cutoff value for the erosion
score. Applying this cutoff value, 28% of etanercept-
treated patients were judged to have erosion that pro-
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gressed, versus 40% of MTX-treated patients. Within
each trial, these figures are meaningful and show that the
active treatment was effective. However, there is little
value in comparing progression between these trials,
because all have assigned different cutoff values.
Interpretation of radiographic results
Clinicians often question whether the measured differ-
ences in radiographic progression between treatment
arms are clinically relevant. To answer this question, long-
term follow-up of other outcomes such as functional dis-
ability and loss of work is required. However, collection of
these long-term data takes several years; therefore, it is
useful to look for circumstantial evidence. Structural joint
damage in clinical trials is assessed in small joints.
However, there is a good correlation between the damage
in small joints with the damage in large joints [24]. There-
fore, an observed reduction in disease progression in
small joints is likely a reflection of the disease course in
large joints. Moreover, there is an association between
structural joint damage and physical function that is
stronger with increasing disease duration [25]. Lastly, it is
important to consider that RA is a chronic disease, and it
can be expected that without treatment, patients will con-
tinue to show progression of structural damage.
As an example, the interpretation of the radiographic
results of the ATTRACT trial are presented here. Are the
findings clinically relevant? All films were scored by the
Sharp/van der Heijde method (range 0 to 440), by two
independent observers, and without knowledge of the
radiograph sequence. The average score of two
observers was used. The median increase in the modified
Sharp score in all patients treated with infliximab plus
MTX was 0.5 (IQR –2.0, 2.5), versus 4.3 (IQR 0.5, 10) in
patients treated with MTX alone [26]. These data imply
that at least 50% of patients treated with infliximab
achieved a progression score of 0.5 or less and that 75%
of patients progressed to a maximum value of 2.5. In
patients treated with MTX alone, 50% of patients showed
an increase of 4.3 and 75% progressed to a maximum
value of 10.
At first glance, when considering the median increase in
joint damage observed in patients treated with MTX alone
in the context of the total range of the scoring system (0 to
440), a median increase of 4 appears clinically insignifi-
cant. In practice, however, it is extremely rare for patients
to have complete destruction of all joints in both hands
and feet and thereby receive a maximum score. Scores
around 100 already represent major destruction. Usually,
the progression score of 4 represents an increase in
erosion and joint space narrowing in several joints.
However, it is difficult to envision how this will affect the
patient. As the maximum erosion score per hand joint is 5,
one could imagine that an increase of 4 would represent
an almost completely eroded hand joint. Thus, a median
increase of 4 is actually a substantial finding. Furthermore,
this especially makes sense if the long duration of the
disease, resulting in an increase of 40 over 10 years, is
taken into account. Assuming a continuation of what was
observed in the trial, 50% of patients receiving MTX alone
will develop eight completely eroded hand joints in the fol-
lowing 10 years and 25% of these patients will reach a
score exceeding 100 (if they started with normal films),
which represents marked joint destruction. In contrast,
50% of patients treated with infliximab will have no pro-
gression of joint destruction in the following 10 years, and
25% of patients will reach a score of 25 points, which rep-
resents five completely eroded hand joints. Furthermore,
recent research has shown that clinical experts consider
an increase of 5 Sharp/van der Heijde points a clinically
meaningful change [23]. Therefore, on the basis of this
expert opinion, 50% of patients treated with MTX alone
had clinically meaningful disease progression, whereas
75% of patients treated with infliximab did not [23].
The ATTRACT trial also analyzed radiographic progres-
sion in individual patients by using the SDD as a cutoff
level. This value (8.6) represented the progression of
disease that was distinguishable from measurement error.
Measurements >8.6 represented significant radiographic
progression. From these results, the number of patients
needed to be treated (NNT) to prevent major progression
can be calculated, where NNT = 1/(% of MTX-only-treated
patients with progression above the SDD [31%] – % of
infliximab-treated patients with progression above the
SDD [6%]) × 100, which yields an NNT of 4. Therefore,
four patients need to be treated with infliximab to prevent
major radiographic progression in one patient. The NNT
value associated with infliximab treatment compares favor-
ably with that of many treatments used to prevent frac-
tures due to osteoporosis, which have an NNT value of
100 to 200.
Conclusion
In summary, although a therapeutic effect on structural
joint damage within a clinical trial setting can be evaluated,
interpreting and comparing radiographic results across
clinical trials can be very hazardous.
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